TEVA-TELMISARTAN TABLET

দেশ: কানাডা

ভাষা: ইংরেজি

সূত্র: Health Canada

সক্রিয় উপাদান:

TELMISARTAN

থেকে পাওয়া:

TEVA CANADA LIMITED

এটিসি কোড:

C09CA07

INN (আন্তর্জাতিক নাম):

TELMISARTAN

ডোজ:

40MG

ফার্মাসিউটিকাল ফর্ম:

TABLET

রচনা:

TELMISARTAN 40MG

প্রশাসন রুট:

ORAL

প্যাকেজ ইউনিট:

28/30/100/500

প্রেসক্রিপশন টাইপ:

Prescription

থেরাপিউটিক এলাকা:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

পণ্য সারাংশ:

Active ingredient group (AIG) number: 0138223001; AHFS:

অনুমোদন অবস্থা:

APPROVED

অনুমোদন তারিখ:

2012-01-06

পণ্য বৈশিষ্ট্য

TEVA-TELMISARTAN
Page 1 of 38
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
TEVA-TELMISARTAN
Telmisartan Tablets
Tablet, 40 mg and 80 mg, Oral
USP
Angiotensin II AT1 Receptor Blocker
Teva Canada Limited
30 Novopharm Court
Toronto, ON
M1B 2K9
Canada
www.tevacanada.com
Date of Initial Authorization:
January 06, 2012
Date of Revision:
August 15, 2023
Submission Control No: 272815
TEVA-TELMISARTAN
Page 2 of 38
RECENT MAJOR LABEL CHANGES
2 CONTRAINDICATIONS
08/2023
7 WARNINGS AND PRECAUTIONS
08/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
............................................................................................
2
TABLE OF CONTENTS
..............................................................................................................
2
PART I:
HEALTH PROFESSIONAL INFORMATION
................................................................... 4
1
INDICATIONS
..................................................................................................................
4
1.1
Pediatrics
...........................................................................................................................
4
1.2 Geriatrics
...........................................................................................................................
4
2
CONTRAINDICATIONS
.....................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
................................................................ 5
4
DOSAGE AND ADMINISTRATION
.....................................................................................
5
4.1 Dosing Considerations
......................................................................................................
5
4.2 Recommended Dose and Dosage Adjustment
................................................................. 5
4.4 Administration
......................................